Revised SPCs: Ozempic (semaglutide) solution for injection in pre-filled pen

The SPC has been updated to incorporate information from a study of semaglutide as add-on to SGLT2 inhibitor treatment (SUSTAIN 9), including efficacy results and safety (rates of hypoglycaemia and gastrointestinal adverse events).

Source:

electronic Medicines compendium